Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users

Jon Owen Ebbert, Lowell C. Dale, Christi Ann Patten, Ivana T Croghan, Darrell R. Schroeder, Thomas P. Moyer, Richard D. Hurt

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

No pharmacotherapies have been shown to increase long-term (≥6-month) abstinence rates among smokeless tobacco (ST) users. Available evidence suggests that underdosing may occur with standard-dose nicotine replacement therapy (NRT) in ST users. We investigated the effect of high-dose nicotine therapy on tobacco withdrawal symptoms among ST users in a randomized, controlled clinical pilot study. A total of 42 ST users using at least 3 cans or pouches per week were randomized to nicotine patch doses of 63, 42, or 21mg/day or placebo for 8 weeks. Multiple daily assessments of tobacco withdrawal and nicotine toxicity were obtained with an electronic diary. During the first week of nicotine patch therapy, we observed a dose-response relationship such that higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.87, p = .009), less negative affect (χ2=3.85, p = .05), and less restlessness (χ2 = 3.90, p = .048). During the second week, higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.77, p = .009). Overall, the frequency of nicotine toxicity symptoms did not differ by dose group. Of specific symptoms, nausea was observed to be more frequent in the 63 mg/day dose group compared with placebo (p = .035). In conclusion, high-dose nicotine patch therapy resulted in a greater reduction of tobacco withdrawal symptoms among ST users using at least 3 cans per week. High-dose nicotine patch therapy is safe and well tolerated in this population of tobacco users.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalNicotine and Tobacco Research
Volume9
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Tobacco Use Cessation Products
Smokeless Tobacco
Substance Withdrawal Syndrome
Tobacco
Nicotine
Arousal
Therapeutics
Placebos
Psychomotor Agitation
Nausea
Drug Therapy
Population

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. / Ebbert, Jon Owen; Dale, Lowell C.; Patten, Christi Ann; Croghan, Ivana T; Schroeder, Darrell R.; Moyer, Thomas P.; Hurt, Richard D.

In: Nicotine and Tobacco Research, Vol. 9, No. 1, 01.2007, p. 43-52.

Research output: Contribution to journalArticle

@article{8911f157bc5f4bf382a211ac58f0174f,
title = "Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users",
abstract = "No pharmacotherapies have been shown to increase long-term (≥6-month) abstinence rates among smokeless tobacco (ST) users. Available evidence suggests that underdosing may occur with standard-dose nicotine replacement therapy (NRT) in ST users. We investigated the effect of high-dose nicotine therapy on tobacco withdrawal symptoms among ST users in a randomized, controlled clinical pilot study. A total of 42 ST users using at least 3 cans or pouches per week were randomized to nicotine patch doses of 63, 42, or 21mg/day or placebo for 8 weeks. Multiple daily assessments of tobacco withdrawal and nicotine toxicity were obtained with an electronic diary. During the first week of nicotine patch therapy, we observed a dose-response relationship such that higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.87, p = .009), less negative affect (χ2=3.85, p = .05), and less restlessness (χ2 = 3.90, p = .048). During the second week, higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.77, p = .009). Overall, the frequency of nicotine toxicity symptoms did not differ by dose group. Of specific symptoms, nausea was observed to be more frequent in the 63 mg/day dose group compared with placebo (p = .035). In conclusion, high-dose nicotine patch therapy resulted in a greater reduction of tobacco withdrawal symptoms among ST users using at least 3 cans per week. High-dose nicotine patch therapy is safe and well tolerated in this population of tobacco users.",
author = "Ebbert, {Jon Owen} and Dale, {Lowell C.} and Patten, {Christi Ann} and Croghan, {Ivana T} and Schroeder, {Darrell R.} and Moyer, {Thomas P.} and Hurt, {Richard D.}",
year = "2007",
month = "1",
doi = "10.1080/14622200601078285",
language = "English (US)",
volume = "9",
pages = "43--52",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users

AU - Ebbert, Jon Owen

AU - Dale, Lowell C.

AU - Patten, Christi Ann

AU - Croghan, Ivana T

AU - Schroeder, Darrell R.

AU - Moyer, Thomas P.

AU - Hurt, Richard D.

PY - 2007/1

Y1 - 2007/1

N2 - No pharmacotherapies have been shown to increase long-term (≥6-month) abstinence rates among smokeless tobacco (ST) users. Available evidence suggests that underdosing may occur with standard-dose nicotine replacement therapy (NRT) in ST users. We investigated the effect of high-dose nicotine therapy on tobacco withdrawal symptoms among ST users in a randomized, controlled clinical pilot study. A total of 42 ST users using at least 3 cans or pouches per week were randomized to nicotine patch doses of 63, 42, or 21mg/day or placebo for 8 weeks. Multiple daily assessments of tobacco withdrawal and nicotine toxicity were obtained with an electronic diary. During the first week of nicotine patch therapy, we observed a dose-response relationship such that higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.87, p = .009), less negative affect (χ2=3.85, p = .05), and less restlessness (χ2 = 3.90, p = .048). During the second week, higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.77, p = .009). Overall, the frequency of nicotine toxicity symptoms did not differ by dose group. Of specific symptoms, nausea was observed to be more frequent in the 63 mg/day dose group compared with placebo (p = .035). In conclusion, high-dose nicotine patch therapy resulted in a greater reduction of tobacco withdrawal symptoms among ST users using at least 3 cans per week. High-dose nicotine patch therapy is safe and well tolerated in this population of tobacco users.

AB - No pharmacotherapies have been shown to increase long-term (≥6-month) abstinence rates among smokeless tobacco (ST) users. Available evidence suggests that underdosing may occur with standard-dose nicotine replacement therapy (NRT) in ST users. We investigated the effect of high-dose nicotine therapy on tobacco withdrawal symptoms among ST users in a randomized, controlled clinical pilot study. A total of 42 ST users using at least 3 cans or pouches per week were randomized to nicotine patch doses of 63, 42, or 21mg/day or placebo for 8 weeks. Multiple daily assessments of tobacco withdrawal and nicotine toxicity were obtained with an electronic diary. During the first week of nicotine patch therapy, we observed a dose-response relationship such that higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.87, p = .009), less negative affect (χ2=3.85, p = .05), and less restlessness (χ2 = 3.90, p = .048). During the second week, higher nicotine patch doses were associated with less decreased arousal (χ2 = 6.77, p = .009). Overall, the frequency of nicotine toxicity symptoms did not differ by dose group. Of specific symptoms, nausea was observed to be more frequent in the 63 mg/day dose group compared with placebo (p = .035). In conclusion, high-dose nicotine patch therapy resulted in a greater reduction of tobacco withdrawal symptoms among ST users using at least 3 cans per week. High-dose nicotine patch therapy is safe and well tolerated in this population of tobacco users.

UR - http://www.scopus.com/inward/record.url?scp=34247842847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247842847&partnerID=8YFLogxK

U2 - 10.1080/14622200601078285

DO - 10.1080/14622200601078285

M3 - Article

C2 - 17365735

AN - SCOPUS:34247842847

VL - 9

SP - 43

EP - 52

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 1

ER -